Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal
Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company, for around $470 million, aiming to strengthen its research pipeline with a potential new Alzheimer's treatment.
Under the agreement, Vigil shareholders will receive $8 per share, along with the possibility of an extra $2 per share through a contingent value right (CVR). This CVR depends on the progress of a drug Vigil is developing to treat Alzheimer's.
If the CVR conditions are met, the total value of the deal could rise to approximately $600 million. The transaction is expected to be finalized in the third quarter and, according to Sanofi, it will not impact its financial guidance for 2025.
Through this acquisition, Sanofi (NASDAQ:SNY) would gain access to VG-3927, an experimental oral therapy for Alzheimer's. The company had already invested $40 million in Vigil in June 2024, securing exclusive negotiation rights for the drug.
However, Vigil's VGL101 monoclonal antibody program is not part of the deal and will be returned to Amgen, the U.S. pharmaceutical firm.
Earlier this month, Sanofi (NASDAQ:SNY) also disclosed plans to invest at least $20 billion in U.S.-based manufacturing and research by 2030, through both its own facilities and collaborations with domestic partners. SNY has surged by nearly 10% since the start of 2025.
While we acknowledge the potential of SNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNY and that has 100x upside potential, check out our report about this cheapest AI stock.
READ MORE: and
Disclosure. None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Former head trader of Denver-based investing company pleads guilty to insider trading
DENVER (KDVR) — A Connecticut man pleaded guilty to an insider trading charge on Friday for actions he took while employed at Denver-based firm Irving Investors. Ryan Squillante, 40, of Weston, Connecticut, was employed as the head of equity trading at Irving Investors at the time of the offense, according to the U.S. Attorney's Office for the District of Connecticut. While there, he received 'material non-public information' about some publicly traded companies. Australian hacker sentenced in May arrested by HSI Denver, faces deportation Prosecutors say that Squillante used MNPI on 15 different occasions between August 2022 and May 2023 for his own benefit, profiting about $220,912 from the transactions, according to the attorney's office. The U.S. Attorney's Office for the District of Connecticut provided an example of one of the times Squillante reportedly received MNPI about a clinical-stage biopharmaceutical company called Praxis Precision Medicines. Praxis is traded on the NASDAQ. The prosecutors said that between Feb. 27, 2023, and March 2, 2023, Squillante 'sold short' over 38,000 shares of Praxis for an average price per share of $3.04. On March 3, prosecutors say Squillante announced poor results of the company's drug trial before the market opened. Following that announcement, Squillante 'covered' the same number of shares at an average price of $1.82 per share, making a profit of about $46,421. Squillante pleaded guilty to securities fraud, which has a maximum term of imprisonment of 20 years. He's scheduled to be sentenced on Aug. 29. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
25 minutes ago
- Yahoo
Teen TikTok skin care craze may be harmful — and expensive, study finds
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being. When Ayva Peña got a phone at age 10, her interest in skin care skyrocketed. At first, she bonded over it with her mother, Giselle Peña. Together, they would have spa days with face masks and take occasional shopping trips to try out new products. But when the Rhode Island mother found a $300 anti-aging face cream in Ayva's medicine drawer, it gave her pause. 'I got very upset. … She's 15 years old,' Peña said. 'It says it makes your skin ageless, improves fine lines, wrinkles and firmness. I was like, 'This is not for you, girl.'' Peña is among a growing number of parents concerned about how content on social media platforms is influencing children and teens into trying out elaborate, often age-inappropriate skin care products. Now, a study published Monday in the journal Pediatrics may confirm those parents' worries. After analyzing beauty routines from 100 TikTok videos by content creators ages 7 through 18, researchers found an average of 11 potentially irritating active ingredients among their regimens, many of which carry a risk of developing skin allergies and increased sun sensitivity. Only a quarter of the lengthy product lists contained sunscreens, however. 'The majority of (children) featured in these videos didn't have any visible acne. They had perfect, clear skin,' said Dr. Molly Hales, the first study author and a board-certified dermatologist in the department of dermatology at Northwestern University's Feinberg School of Medicine. 'For many of them, the harms probably outweigh any potential benefits.' Between the dozens of daily serums, moisturizers, toners and cleansers featured in the videos, the average routine was six steps long, costing about $168 — with some more than $500 — for one month's worth of product, according to the study. 'When you have kids waking up at 5:30 in the morning on a school day to have enough time to layer on these complicated regimens, I think it becomes less about health and more (about) pursuing an idea of beauty that is unrealistic and problematic,' said Hales, who is also a postdoctoral research fellow at Feinberg. The findings raise serious ethical questions about how social media content influences young people in their everyday lives, she added A TikTok spokesperson, noting that this type of content is 'common across all media,' said the platform is only for users ages 13 and older, and any creators suspected to be under 13 are removed. Additionally, they said that TikTok works with third-party doctors and experts in adolescent development to implement safeguarding policies. Most of the studied skin care routines lacked a form of sunscreen but contained products that could increase sun sensitivity and risk of skin cancer, the authors found. Common active ingredients found in recommended skin products were alpha hydroxy acids or AHAs, mild chemical exfoliants that help remove top layers of skin cells, Hales said. While they have the intended effect of evening skin tone and creating a more youthful appearance, they are known to make the skin more vulnerable to the sun's ultraviolet rays. 'I would recommend daily sunscreen use for all ages and regimens, but especially for those using these (AHAs),' Hales said. 'It's a necessary step to prevent permanent skin damage.' Those AHAs, as well as vitamin-based ingredients such as niacinamide, are also considered potential irritants, carrying side effects such as redness and dryness, especially with overuse. 'In many cases, the girls may not have realized they were applying the same active ingredient again and again, which just increases the risk of irritation,' said Dr. Tara Lagu, senior study author and adjunct lecturer of medicine and medical social sciences at Feinberg. More than half the products contained fragrance — a common cause of allergic contact dermatitis — and 20 other inactive ingredients that are known allergens, according to the study. 'Misinformation is a big issue on social media, but especially for these content creators younger than 18,' said Dr. Sonal Shah, a board-certified dermatologist in Cleveland and director of pediatric dermatology at University Hospitals Rainbow Babies & Children's Hospital. Shah was not involved in the study. 'These are sources that perhaps don't have a scientific background and are not well read in the science behind a lot of these products, how they work, or what risks they carry,' Shah said, adding that there are board-certified dermatologists on TikTok that could offer more credible advice. Other concerning trends Shah has seen in her practice, but were not mentioned in the study, include mechanical exfoliants, such as scrubbing wands or cleansers containing plastic microbeads, which are often too rough for facial skin. The study also noted that many of the creators were offering tips relevant to those with lighter complexions, which may exclude the unique skin care considerations of darker complexions while perpetuating harmful ideals of 'brighter' skin associated with whiteness. Both Shah and Hales recommend children under 18 who are not dealing with acne use a gentle cleanser with no active ingredients, paired with a fragrance-free moisturizer and a daily mineral sunscreen. In general, children will not benefit from anti-aging products that promise to boost skin elasticity or eliminate fine lines, Shah said. In these young ages, collagen production is at the highest it will ever be. As children reach puberty, however, they may produce more acne-causing hormones. In those cases, Shah recommends adding an over-the-counter product with salicylic acid or a low percentage of benzoyl peroxide. 'Their skin care does not have to be complicated and does not have to be very expensive,' Shah said. Parents 'can talk to a board-certified dermatologist or pediatric dermatologist if there are skin concerns that are significant or don't respond to over-the-counter treatment.' Ultimately, if parents are concerned about their child's skin care regimen, they should talk about it, said Jennifer Harriger, a professor of psychology at Pepperdine University who studies childhood development, in a statement. 'I think that it is always best to have open conversations with children about the messages they see on social media as well as their own intentions behind purchasing particular skincare products,' said Harriger, who was not involved in the study. It's also important to keep an open mind, understanding the social dimension of youth beauty and wellness content, Hales said. 'These videos show a kind of playful self-expression that's very appealing to this age group,' Hales said. 'These are girls who are just starting to develop their own sense of independent identity, how they present (themselves) in the world, their gender identity, and in many cases what it means to be a girl in our society.'
Yahoo
30 minutes ago
- Yahoo
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and runs through March. Immunizations begin in early fall and these advance shipments provide confidence for healthcare providers to support their efforts. Demand has continued to increase since the launch of Beyfortus, the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy through a typical RSV season and an unparalleled body of real-world evidence. Sanofi, in collaboration with its partner AstraZeneca, has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023. Current supply for the upcoming season already matches the total doses distributed last year and production continues. Last season in the US, enough doses were produced to cover every infant — a benchmark that reflects both Sanofi's and AstraZeneca's global commitment to ensuring timely access for all infants. Executive Vice President, Vaccines'Our third year of providing RSV protection marks a transformative era in infant health. Backed by more than 40 real-world studies involving 250,000 immunized infants, Beyfortus has consistently proven itself as an effective RSV immunization. To meet growing demand since launch, we have meticulously primed our global distribution network to ensure Beyfortus will continue to deliver significant public health impact and offer high, sustained efficacy for infants regardless of underlying health conditions or the timing of when they are born.' Beyfortus duration of protection extended through six months in the EUThis year's EU shipments are marked by an important change to the Beyfortus EU label extending the duration of protection through six months, so Beyfortus can continue to offer season-long protection for all infants, including older babies immunized just before the RSV season begins. More than six million babies have been immunized worldwide and millions more will be immunized this season in more than 40 countries to help protect them from the potentially devastating impact of RSV disease. All infants are at risk from RSVRSV is a highly contagious virus infecting two out of three infants in their first year of life and nearly all children by their second birthday. RSV is the main cause of lower respiratory tract disease and a leading cause of hospitalization in all infants worldwide, with most hospitalizations occurring in healthy infants born at term. With an extended half-life of 71 days, Beyfortus stands apart as the longest-acting monoclonal antibody for the prevention of RSV lower respiratory tract disease in infants, and the only RSV immunization designed to protect all infants born before or during the RSV season, at term or preterm, healthy or with underlying conditions. Administration can be timed to coincide with the RSV season and provided directly to newborns and infants as a single dose. Beyfortus offers rapid protection without requiring activation of the immune system. Beyfortus is also designed to protect children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus was approved and granted special designations to expedite development across major geographies including the US, the EU, Japan and China. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
